H₂ inhalation therapy in patients with moderate COVID-19 (H₂COVID): a prospective ascending-dose phase I clinical trial.

ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a serious global health crisis, resulting in millions of reported deaths since its initial identification in China in November 2019. The global disparities in immunization access emphasize the urgent need for ongoing research into therapeutic interventions. This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19. H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation, particularly when administered early in conjunction with nasal oxygen therapy. This phase I study, characterized by an open-label, prospective, monocentric, and single ascending-d

SUBMITTER: Salomez-Ihl C 

PROVIDER: S-EPMC11304737 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature